# BI-1206

Source: https://onco.cc/drugs/bi-1206/  
OnCo record `bi-1206` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BI-1206 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for non-small-cell lung cancer, uveal melanoma and non-Hodgkin lymphoma and other cancers.

## Summary

BI-1206 (BI1206) is a monoclonal antibody from BioInvent International, with Merck & Co. as partner. A high-affinity monoclonal antibody that selectively binds FcγRIIB (CD32B), the only inhibitory member of the FcγR family, intended to address a mechanism of resistance to PD-1 inhibition; tested with pembrolizumab and with rituximab. Its furthest stage is phase 2, for non-small-cell lung cancer, uveal melanoma, non-Hodgkin lymphoma and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/2a NCT04219254 (with pembrolizumab, MSD collaborator) recruiting (registry, checked 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: BI1206
- Tags: pipeline; ctgov-ingest
- Code: BI-1206
- Modality: Monoclonal antibody
- Mechanism: A high-affinity monoclonal antibody that selectively binds FcγRIIB (CD32B), the only inhibitory member of the FcγR family, intended to address a mechanism of resistance to PD-1 inhibition; tested with pembrolizumab and with rituximab.

## Sources

- BioInvent International: bioinvent.com: https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1206pembrolizumab
- BioInvent International: bioinvent.com: https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1206pembrolizumab
- ClinicalTrials.gov: trials of BI-1206: https://clinicaltrials.gov/search?intr=BI-1206

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [FCGR2B](https://onco.cc/targets/fcgr2b/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct04219254/)

---
JSON: https://onco.cc/api/v1/entities/bi-1206.json